Market Closed - Nasdaq 04:30:00 2024-03-27 pm EDT 5-day change 1st Jan Change
2.94 USD -0.17% Intraday chart for Avinger, Inc. -10.91% +8.49%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Avinger, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (AVGR) AVINGER Posts Q4 Revenue $1.9M, vs. Street Est of $2.52M MT
Transcript : Avinger, Inc., Q4 2023 Earnings Call, Mar 20, 2024
Avinger, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Avinger in Equity Funding Partnership With Chinese Medical Device Firm, Unveils Debt-Terms Extension; Shares Rise Premarket MT
Avinger, Inc. Appoints Jonathon Zhong Zhao as Class II Member of the Board CI
Zylox-Tonbridge Enters Licensing, Investment Contracts with American Innovative Medical Device Maker MT
Avinger, Inc. Announces New Strategic Partnership with Zylox-Tonbridge Medical Technology Co., Ltd CI
Top Premarket Decliners MT
Avinger, Inc. Enters Amendment No. 7 to the Term Loan Agreement with CRG Partners III L.P CI
Avinger, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Avinger, Inc., Q3 2023 Earnings Call, Oct 26, 2023
Earnings Flash (AVGR) AVINGER Posts Q3 Revenue $1.8M, vs. Street Est of $2.39M MT
Top Premarket Decliners MT
Top Midday Gainers MT
Wall Street Set to Open Marginally Lower as Fed Kicks Off September Policy Meeting MT
Top Premarket Gainers MT
Sector Update: Health Care Stocks Lower Late Afternoon MT
Sector Update: Health Care MT
Top Midday Gainers MT
Avinger, Inc. Initiates Full Commercial Launch of Tigereye St Image-Guided CTO Crossing Device CI
Avinger to Convert 12% of Term Debt With CRG Partners III Into Equity MT
Avinger, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Transcript : Avinger, Inc., Q2 2023 Earnings Call, Jul 27, 2023
Avinger, Inc. Receives 510(K) Clearance for Pantheris LV Image-Guided Atherectomy System CI
Chart Avinger, Inc.
More charts
Avinger, Inc. is a commercial-stage medical device company. The Company designs, manufactures, and sells real-time, image-guided, minimally invasive catheter-based systems that are used by physicians to treat patients with peripheral artery disease (PAD). Its Lumivascular platform includes the Lightbox real-time imaging console, the Ocelot and Tigereye family of catheters, which are image-guided catheters designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO), and the Pantheris family of catheters, its image-guided atherectomy family of catheters designed to allow physicians to remove arterial plaque in PAD patients. Its Pantheris is a single-use product and provides physicians with the ability to see a cross-sectional view of the peripheral artery to guide the removal of blockages throughout the procedure. It has also developed a line extension of its Pantheris image-guided atherectomy platform, Pantheris SV (Small Vessel).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.94 USD
Average target price
5 USD
Spread / Average Target
+70.07%
Consensus
  1. Stock
  2. Equities
  3. Stock Avinger, Inc. - Nasdaq
  4. News Avinger, Inc.
  5. Avinger : B. Riley Starts Avinger at Buy with $2.50 PT, Says Well-Positioned to Execute on Growth Strategy